Evidence map›Paper›PMID 35679409›Full record

ArticleScience (New York, N.Y.)2022

Enantioselective hydrogen-bond-donor catalysis to access diverse stereogenic-at-P(V) compounds.

Katherine C Forbes, Eric N Jacobsen

Abstract read
In one paragraph

Article in Science (New York, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Rh-Catalyzed Enantioselective Single-Carbon Insertion of Alkenes.Journal of the American Chemical Society · 2024
    Article
  15. Catalysis of an SNature · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Development of Enantioselective Lithium-Isothiourea-Boronate-Catalyzed Matteson Homologations.Synlett : accounts and rapid communications in synthetic organic chemistry · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Katherine C ForbesDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-5654-6780
Eric N JacobsenDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-7952-3661

Funding

CHIRAL COMPLEXES DESIGNED TO CATALYZE ORGANIC REACTIONSR01GM043214 · NIGMS · UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN · PI JACOBSEN, ERIC N · 1991 to 2023
$9.4M
Chiral Catalysts Designed to Catalyze Organic ReactionsR37GM043214 · NIGMS · HARVARD UNIVERSITY · PI JACOBSEN, ERIC N · 2002 to 2011
$6.6M
NIGMS NIH HHS R01 GM043214NIGMS NIH HHS R37 GM043214
6 · The paper itself

Abstract

The stereoselective synthesis of molecules bearing stereogenic phosphorus(V) centers represents an enduring challenge in organic chemistry. Although stereospecific nucleophilic substitution at P(V) provides a general strategy for elaborating optically active P(V) compounds, existing methods for accessing the requisite chiral building blocks rely almost entirely on diastereocontrol using chiral auxiliaries. Catalytic, enantioselective methods for the synthesis of synthetically versatile stereogenic P(V) building blocks offer an alternative approach to stereogenic-at-P(V) targets without requiring stoichiometric quantities of chiral control elements. Here, we report an enantioselective hydrogen-bond-donor-catalyzed synthesis of aryl chlorophosphonamidates and the development of these products as versatile chiral P(V) building blocks. We demonstrate that the two leaving groups on these chlorophosphonamidates can be displaced sequentially and stereospecifically to access a wide variety of stereogenic-at-P(V) compounds featuring diverse substitution patterns.

Identifiers

PMID35679409
PMCPMC9427129

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.